Dernières nouvelles pour IDEXX Laboratories (NASDAQ:IDXX) Stock

IDEXX Laboratories

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.

IDEXX Laboratories Inc

IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for IDEXX Laboratories, presenting an average target of $517.0, a high estimate of $580.00, and a low estimate of $420.00. Observing a 4.82% increase, the current average has risen from the previous average price target of $493.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1749668452_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of IDEXX Laboratories's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Clark</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$580.00</td>
<td>$515.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$510.00</td>
<td>$460.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$558.00</td>
<td>$548.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$420.00</td>
<td>$450.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to IDEXX Laboratories. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of IDEXX Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for IDEXX Laboratories's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of IDEXX Laboratories's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/IDXX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on IDEXX Laboratories analyst ratings.</a>
<h2>All You Need to Know About IDEXX Laboratories</h2>
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
<h3>A Deep Dive into IDEXX Laboratories's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: IDEXX Laboratories's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 3.56%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: IDEXX Laboratories's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 24.31%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): IDEXX Laboratories's ROE excels beyond industry benchmarks, reaching 15.95%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): IDEXX Laboratories's ROA stands out, surpassing industry averages. With an impressive ROA of 7.46%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.73.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

IDXX

IDEXX Laboratories Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Leerink Partners analyst Daniel Clark maintains IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) with a Outperform and raises the price target from $515 to $580.

News

Price Target

Leerink Partners Maintains Outperform on IDEXX Laboratories, Raises Price Target to $580

A mix of bullish catalysts is poised to lift investor sentiment Wednesday, as President Donald Trump confirmed a China trade deal and fresh inflation data came in softer <a href="https://www.benzinga.com/markets/economic-data/25/06/45881899/inflation-resumes-climb-in-may-but-tariffs-have-yet-to-hit-consumers">than expected for May.</a>
Trump declared a sweeping new trade agreement with China via Truth Social following two days of negotiations in London, suggesting major concessions from Beijing and lighter U.S. obligations.
&#8220;Full magnets, and any necessary rare earths, will be supplied, up front, by China,&#8221; Trump said, adding that the U.S. would reciprocate by allowing Chinese students access to U.S. colleges. 
The deal, pending final approval with Chinese President Xi Jinping, includes a significant tariff shift. The U.S. will continue applying tariffs totaling 55% on selected Chinese imports, while China will impose a 10% tariff rate on U.S. goods.
<h3 class="wp-block-heading">Inflation Rises Less Than Expected In May, Easing Tariff Anxiety</h3>
U.S. consumer inflation was softer than expected in May, reinforcing expectations for Federal Reserve rate cuts later this year.
The Consumer Price Index rose 2.4% from a year earlier, undercutting the 2.5% forecasted by economists and edging slightly above April's 2.3% reading. On a monthly basis, prices climbed just 0.1%, slower than both the prior month's 0.2% and the consensus estimate.
Core CPI—which excludes food and energy—held steady at 2.8% year over year, missing the 2.9% projection. Month over month, core prices advanced only 0.1%, undershooting the expected 0.3%.
Energy prices were a major drag, falling 1% in May. Gasoline plunged 2.6%, reversing the prior month's rise. On the flip side, services like medical care and motor vehicle insurance saw upward pressure.
&#8220;With lower-than-expected numbers across the board and a trade deal with China that was agreed to in London, the narrative around tariff-induced inflation should subside,&#8221; said Chris Zaccarelli, chief investment officer for Northlight Asset Management.
<h3 class="wp-block-heading">How Close Are We to New Highs?</h3>
In premarket trading, the S&amp;P 500 index traded at 6,050, up 0.20%, while the Nasdaq 100 added 0.25% to reach 21,990.
The Dow Jones Industrial Average gained 0.1% to 42,924.
Both the S&amp;P 500 and Nasdaq 100 are now less than 2 percentage points from their all-time highs, at 1.6% and 1.1% away, respectively.
According to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a> platform, top-gainers within large-cap stocks following the release of the inflation included:
<ul class="wp-block-list">
<li>CoreWeave Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWE#NASDAQ">CRWE</a>) gained 3.57% to $159.70</li>
<li>NICE Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) rose 3.33% to $179.00</li>
<li>Best Buy Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) added 3.14% to $76.00</li>
<li>Textron Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) climbed 3.03% to $78.15</li>
<li>Honda Motor Co. Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) increased 2.97% to $29.36</li>
<li>Amer Sports Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>) rose 2.86% to $38.69</li>
<li>IDEXX Laboratories Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) gained 2.85% to $540.00</li>
<li>Chewy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) advanced 2.74% to $43.40</li>
<li>Skyworks Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) jumped 2.67% to $75.98</li>
<li>Teradyne Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) added 2.59% to $90.47</li>
</ul>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45870128/meta-platforms-enters-its-most-bullish-month-a-return-to-record-highs-in-sight">Meta Platforms Enters Its Most Bullish Month: A Return To Record Highs In Sight?</a></li>
</ul>
Photo: Shutterstock<a href="https://www.benzinga.com/markets/large-cap/25/06/45870128/meta-platforms-enters-its-most-bullish-month-a-return-to-record-highs-in-sight"> </a>

Equities

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

Tech

ETFs

CHWY

CRWE

NICE

SWKS

Wall Street Eyes Record Highs As Trump Seals China Deal, Soft Inflation Eases Tariff Jitters

Three U.S. lawmakers have disclosed recent purchases of a pet healthcare company just weeks before a biotech bill that could benefit the company's business was introduced in Congress.
What Happened: On Tuesday, Nancy Pelosi Stock Tracker, an X account that monitors U.S. lawmakers&#8217; financial disclosures, reported that Rep. April Delaney (R-MD), Jefferson Shreve (R-IN), and Rob Bresnahan (R-PA) purchased shares of IDEXX Laboratories Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) in early to mid-April and May.
The timing has drawn scrutiny, as all three lawmakers sit on committees directly tied to the &#8220;National Biotech Initiative Act of 2025,&#8221; a bill aimed at expanding federal funding for biotechnology research and development.
The legislation, introduced on April 9, was referred to several committees, including agriculture and foreign affairs, on which each of the three lawmakers serves.
See Also: <a href="https://www.benzinga.com/markets/tech/25/06/45877761/ross-gerber-calls-out-warner-bros-discovery-ceo-david-zaslav-saying-hes-created-zero-value-after-the-conglomerate-announced-plans-to-split-into-two-companies-by-2026">Ross Gerber Calls Out Warner Bros. Discovery CEO David Zaslav, Saying He&#8217;s Created &#8216;Zero Value&#8217; After The Conglomerate Announced Plans To Split Into Two Companies By 2026</a>
According <a href="https://www.congress.gov/bill/119th-congress/house-bill/2756/text">to</a> the bill&#8217;s text, the aim is to &#8220;boost biotech funding research/development for biotech products across the country,&#8221; resulting in substantial tailwinds for companies such as IDEXX. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Breaking&#x1f6a8;: A third Politician just bought IDEXX Labs <a href="https://twitter.com/search?q=%24IDXX&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$IDXX</a> !! This time it&#39;s Rep. Rob Bresnahan who sits on the House Agriculture Committee Why does that matter? All three of the politicians who bought sit on committees overseeing an Act that would directly benefit the… <a href="https://t.co/5ZZdjbcgGE">pic.twitter.com/5ZZdjbcgGE</a>
&mdash; Nancy Pelosi Stock Tracker &#x265f; (@PelosiTracker_) <a href="https://twitter.com/PelosiTracker_/status/1932466838304342490?ref_src=twsrc%5Etfw">June 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The Pelosi Tracker post states that Shreve bought shares on April 6, Delaney followed on April 7, and Bresnahan made his purchase on May 14. While congressional stock trading is legal, it&#8217;s been quite controversial, with <a href="https://www.benzinga.com/trading-ideas/25/05/45552223/exclusive-congress-trading-ban-sees-huge-support-in-reader-poll-heres-the-percent-that-say-let-them-keep-trading-stocks">growing calls for a ban</a> on trading stocks, options and ETFs by members of Congress in recent years.
Why It Matters: Economist Justin Wolfers recently called it &#8220;simply absurd&#8221; that Congressional representatives are <a href="https://www.benzinga.com/news/25/04/44831847/justin-wolfers-when-tweets-move-markets-lawmakers-trading-stocks-is-simply-absurd">allowed to trade stocks</a>, even while receiving &#8220;top secret briefings.&#8221;
It is &#8220;absolutely clear they're using their inside knowledge to get better returns,&#8221; he says, adding that this is not &#8220;how we want to pay our Congressmen.&#8221;
Former House Speaker Nancy Pelosi's portfolio famously outperformed many hedge funds, posting returns of 65% in 2023 and 54% in 2024. But several lesser-known members of Congress have reportedly <a href="https://in.benzinga.com/25/01/42860759/10-best-stock-traders-in-congress-in-2024-where-do-nancy-pelosi-pete-sessions-susan-collins-marjorie-taylor-greene-rank?_gl=1&#x2A;70oecc&#x2A;_gcl_au&#x2A;OTU0MzA1MzE4LjE3NDcwMTIxNDM.&#x2A;_ga&#x2A;ZGVsZXRlZA..&#x2A;_ga_V7ZK73W7N0&#x2A;czE3NDk2MjY5MDkkbzE3NCRnMSR0MTc0OTYzMDI4NCRqMjUkbDAkaDA.">achieved even greater gains</a>, between 70% and 149%, fueling public outcry over perceived conflicts of interest.
Price Action: Shares of IDEXX Laboratories were up 1.41% on Tuesday, trading at $525.93, and are down 0.18% after hours.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="147" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11042753/Screenshot-2025-06-11-at-1.57.40-PM-1024x147.png" alt="" class="wp-image-945758" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11042753/Screenshot-2025-06-11-at-1.57.40-PM-1024x147.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11042753/Screenshot-2025-06-11-at-1.57.40-PM-300x43.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11042753/Screenshot-2025-06-11-at-1.57.40-PM-768x110.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11042753/Screenshot-2025-06-11-at-1.57.40-PM.png 1534w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
According to Benzinga&#8217;s Edge Stock Rankings, Idexx scores high on Momentum and Growth, but fares poorly on Value and Quality. The stock has a favorable price trend in the short, medium, and long term. Check <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here</a> for deeper insights into the stock, its peers and competitors.
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45877457/josh-hawley-peter-welch-propose-raising-federal-minimum-wage-to-15-by-2026-tied-to-inflation">Josh Hawley, Peter Welch Propose Raising Federal Minimum Wage To $15 By 2026, Tied To Inflation</a></li>
</ul>
Photo courtesy: rafapress / Shutterstock.com

Politics

Three Lawmakers Bought This Biotech Stock Before Supporting A Bill That Could Boost Its Value: It's Now Up 44%

The Catalyst&nbsp;Cortisol Test provides veterinarians with real-time critical insights when evaluating dogs for Addison's disease and Cushing's syndrome

IDEXX Unveils Catalyst Cortisol Test To Support Early Detection And Ongoing Management Of Canine Endocrine Disorders

IDEXX Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NYSE">IDXX</a>) short percent of float has risen 5.63% since its last report. The company recently reported that it has 3.03 million shares sold short, which is 4.88% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.73 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>IDEXX Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749045628_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for IDEXX Laboratories has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing IDEXX Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, IDEXX Laboratories's peer group average for short interest as a percentage of float is 5.35%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

What Does the Market Think About IDEXX Laboratories?

IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) has outperformed the market over the past 15 years by 8.47% on an annualized basis producing an average annual return of 20.35%. Currently, IDEXX Laboratories has a market capitalization of $40.65 billion. 
Buying $1000 In IDXX: If an investor had bought $1000 of IDXX stock 15 years ago, it would be worth $16,099.18 today based on a price of $501.57 for IDXX at the time of writing.
<h3>IDEXX Laboratories's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748272513_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) has outperformed the market over the past 20 years by 3.16% on an annualized basis producing an average annual return of 11.41%. Currently, IDEXX Laboratories has a market capitalization of $40.59 billion. 
Buying $1000 In IDXX: If an investor had bought $1000 of IDXX stock 20 years ago, it would be worth $8,586.83 today based on a price of $500.87 for IDXX at the time of writing.
<h3>IDEXX Laboratories's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747868455_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Stifel analyst Jonathan Block maintains IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) with a Hold and raises the price target from $460 to $510.

Stifel Maintains Hold on IDEXX Laboratories, Raises Price Target to $510

Daniel M Junius, Director at IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>), reported a large exercise of company stock options on May 14, according to a new SEC filing.
What Happened: Junius, Director at IDEXX Laboratories, exercised stock options for 2,683 shares of IDXX stock. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000874716/000087471625000090//Archives/edgar/data/874716/000087471625000090/0000874716-25-000090-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The exercise price of the options was $263.81 per share.
Currently, IDEXX Laboratories shares are trading down 0.02%, priced at $509.31 during Thursday's morning. This values Junius's 2,683 shares at $658,691.
<h3>Delving into IDEXX Laboratories's Background</h3>
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
<h3>Breaking Down IDEXX Laboratories's Financial Performance</h3>
Revenue Growth: IDEXX Laboratories displayed positive results in 3 months. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 3.56%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 62.44%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 2.98, IDEXX Laboratories showcases strong earnings per share.
</li>
</ul>
Debt Management: With a high debt-to-equity ratio of 0.73, IDEXX Laboratories faces challenges in effectively managing its debt levels, indicating potential financial strain.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: IDEXX Laboratories's P/E ratio of 47.08 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 10.72 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Boasting an EV/EBITDA ratio of 32.47, IDEXX Laboratories demonstrates a robust market valuation, outperforming industry benchmarks.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000874716">Check Out The Full List Of IDEXX Laboratories's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Daniel M Junius At IDEXX Laboratories Capitalizes: Options Exercised, Resulting In $658K

Sophie V Vandebroek, Board Member at IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>), reported a large exercise of company stock options on May 13, according to a new SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000874716/000087471625000088//Archives/edgar/data/874716/000087471625000088/0000874716-25-000088-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday revealed that Vandebroek, Board Member at IDEXX Laboratories in the Health Care sector, exercised stock options for 1,279 shares of IDXX stock. The exercise price of the options was $283.59 per share.
IDEXX Laboratories shares are trading down 0.0% at $509.13 at the time of this writing on Wednesday morning. Since the current price is $509.13, this makes Vandebroek's 1,279 shares worth $288,465.
<h3>All You Need to Know About IDEXX Laboratories</h3>
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
<h3>Financial Insights: IDEXX Laboratories</h3>
Revenue Growth: Over the 3 months period, IDEXX Laboratories showcased positive performance, achieving a revenue growth rate of 3.56% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 62.44%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): IDEXX Laboratories's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 2.98.
</li>
</ul>
Debt Management: IDEXX Laboratories's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.73, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Assessing Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 47.05 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 10.71, IDEXX Laboratories's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): IDEXX Laboratories's EV/EBITDA ratio of 32.45 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000874716">Check Out The Full List Of IDEXX Laboratories's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Decision: Sophie V Vandebroek Exercises Options At IDEXX Laboratories For $288K

IDEXX Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NYSE">IDXX</a>) short percent of float has risen 5.92% since its last report. The company recently reported that it has 3.00 million shares sold short, which is 4.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>IDEXX Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746802832_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for IDEXX Laboratories has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing IDEXX Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, IDEXX Laboratories's peer group average for short interest as a percentage of float is 4.13%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is the Market Bullish or Bearish on IDEXX Laboratories?

Morgan Stanley analyst Erin Wright maintains IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) with a Overweight and raises the price target from $548 to $558.

Morgan Stanley Maintains Overweight on IDEXX Laboratories, Raises Price Target to $558

WIIM

IDEXX Laboratories shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 EPS guidance above estimates. Also, the company raised its FY25 sales guidance with its midpoint above estimates.

IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) raises FY2025 GAAP EPS guidance from $11.74-$12.24 to $11.93-$12.43 vs $11.91 analyst estimate. Raises FY2025 sales outlook from $4.05 billion-$4.17 billion to $4.09 billion-$4.21 billion vs $4.12 billion estimate.

Guidance

IDEXX Laboratories Raises FY2025 GAAP EPS Guidance from $11.74-$12.24 to $11.93-$12.43 vs $11.91 Est; Raises FY2025 Sales Guidance from $4.05B-$4.17B to $4.09B-$4.21B vs $4.12B Est

Earnings

Earnings Beats

IDEXX Laboratories Q1 Adj. EPS $2.91 Beats $2.85 Estimate, Sales $998.43M Beat $998.15M Estimate

AAMI

AAPL

ABNB

ACCO

ADPT

AGCO

AGIO

ALHC

ALKS

ALNY

ALSN

AMGN

AMWL

AMZN

APLE

APTV

ARDX

ARVN

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CARR

CART

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

DUOL

DXCM

ECVT

ELME

Earnings Scheduled For May 1, 2025

IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) has outperformed the market over the past 10 years by 11.03% on an annualized basis producing an average annual return of 21.28%. Currently, IDEXX Laboratories has a market capitalization of $35.41 billion. 
Buying $100 In IDXX: If an investor had bought $100 of IDXX stock 10 years ago, it would be worth $669.58 today based on a price of $436.97 for IDXX at the time of writing.
<h3>IDEXX Laboratories's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745970316_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In IDEXX Laboratories 10 Years Ago Would Be Worth Today

Looking into the current session, IDEXX Laboratories Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) shares are trading at $409.49, after a 0.70% increase. Moreover, over the past month, the stock increased by 0.04%, but in the past year, decreased by 15.47%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1745344821_0_0.png" alt="Past Year Chart" />

<h3>How Does IDEXX Laboratories P/E Compare to Other Companies?</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 78.64 in the Health Care Equipment &amp; Supplies industry, IDEXX Laboratories Inc. has a lower P/E ratio of 38.11. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1745344821_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

A Look Into IDEXX Laboratories Inc's Price Over Earnings

Stifel analyst Jonathan Block maintains IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) with a Hold and lowers the price target from $450 to $420.

Stifel Maintains Hold on IDEXX Laboratories, Lowers Price Target to $420

Press Releases

IDEXX Laboratories Announces Increase in Share Repurchase Program Authorization

SR Inc Announces 2024 SBER Awards: Top Honors Go to Synopsys, Nell Triplett of Juniper Networks, and IDEXX

IDEXX Laboratories to Release 2024 Fourth Quarter and Full Year Financial Results

IDEXX Announces Groundbreaking Cancer Dx Panel with Affordable Early Detection Test for Canine Lymphoma

IDEXX Laboratories Announces Fourth Quarter and Full Year 2024 Results

IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences

IDEXX Laboratories to Release 2025 First Quarter Financial Results

IDEXX Laboratories Announces First Quarter Results

IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day

Third Expansion of IDEXX's Catalyst Platform in Under a Year Delivers Critical Insights to Veterinarians Evaluating Canine Patients for Endocrine Disorders

Comments

IDEXX Laboratories

Actualités

Dernières nouvelles pour IDEXX Laboratories (NASDAQ:IDXX) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL